Fasiglifam (TAK-875) is primarily investigated for its potential therapeutic applications in managing type 2 diabetes. It functions as a GPR40 agonist, targeting the G protein-coupled receptor 40, which is expressed in pancreatic beta cells. By activating GPR40, it enhances glucose-dependent insulin secretion, helping to regulate blood sugar levels in patients with diabetes. This mechanism offers a promising approach to diabetes treatment, as it stimulates insulin release only in response to elevated glucose levels, thereby reducing the risk of hypoglycemia. Clinical studies have explored its efficacy and safety, showing potential as an oral antidiabetic agent. However, development was suspended in 2013 due to concerns related to liver toxicity observed in some trials.